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 The uses of engineered nanomaterials have expanded in biomedical technology 
and consumer manufacturing. Exposure to particulate matter has been demonstrated to 
negatively influence cardiovascular health and expand myocardial infarction. 
Furthermore, pulmonary exposure to various engineered nanomaterials has, likewise, 
demonstrated the ability to exacerbate cardiac ischemia reperfusion (I/R) injury.  We 
hypothesized that pulmonary exposure to AgNP induces cardiovascular toxicity in the 
form of expanded I/R injury, electrical dysfunction and inducing a persistent increase in 
circulating proinflammatory cytokines. To test this hypothesis, we exposed male SD rats 
to an intratracheal (IT) instillation of 200 µg of 20 or 110 nm polyvinylprryolidone (PVP) 
or citrate capped AgNP, in 200 l of the respective PVP or citrate vehicle. Serum 
samples were collected prior to instillation and 1, 3, 6, 24, 48, 72, and 168 hours 
following instillation. Serum samples were analyzed by multiplex assay for 
concentrations of: G-CSF, GM-CSF, MIP-1α, IL -1β, IL-2, IL-5, IL-6, IL-10, IL-13, IL-17α, 
IL-18, MCP-1, IFNγ, RANTES, and TNF-α. Twenty four and 168 hours after IT 
exposure, cardiac ischemia was induced by left anterior descending coronary artery 
ligation for 20 minutes followed by 2 hours of reperfusion. Intraoperative ECG was 
monitored throughout cardiac I/R surgery for heart rate (HR), PR interval, and QT 
 
 
 
interval. To test the impact of silver ion exposure on cardiac I/R injury we administered 
200 l of 0.01 mg/mL, 0.1 mg/mL, or 1 mg/mL silver acetate (AgAc) and induced 
cardiac I/R 24 hours later.  Intratracheal instillation of AgNP resulted in expansion of I/R 
injury for both sizes of citrate and PVP capped AgNP at both 24 hours and 168 following 
instillation; exposure to 0.1 and 1 mg/mL AgAc also resulted in expansion of I/R injury. 
Intratracheal instillation of AgNP did not result in increased serum concentrations of 
selected proinflammatory cytokines, however post I/R serum levels of IL-2, IL-6, and IL-
18 were significantly elevated in rats exposed to 20 nm PVP capped AgNP compared to 
vehicle controls at 24 hours post instillation. Instillation of AgNP had no impact on HR or 
QT interval. However, exposure to 20 nm AgNP resulted in a differential prolongation or 
shortening of PR interval during reperfusion based on capping agent. In conclusion IT 
instillation of AgNP exacerbates cardiac I/R injury 24 and 168 hours following 
instillation, without inducing a strong systemic inflammatory response or electrical 
dysfunction.  Exposure to AgNP may result in a sensitization of the immune system in 
response to a secondary insult (e.g., cardiac I/R) which are largely correlated with 
capping agents and particle size and may drive expansion of I/R injury at 24 and 168 
hours following IT instillation of AgNP. 
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 CHAPTER 1 
INTRODUCTION 
1.1. PROBLEM and APPROACH 
Cardiovascular disease remains the leading cause of mortality worldwide. Recent 
investigations have demonstrated that pulmonary exposure to particulate matter can negatively 
impact cardiovascular health and may result in an expansion of subsequent myocardial 
infarction (13, 14, 29, 67).  Ambient particulate material impact on cardiovascular health has 
served as a backdrop concern raising questions regarding the potential exposure risks to the 
plethora of engineered particle materials (10, 11). In recent decades, the uses of engineered 
nanomaterial rapidly expanded, and investigation into the potential toxicity of new forms of 
particulate matter has grown in kind. Inhalation of particulate matter can be a primary route of 
exposure and is the subject of much current investigation. The information regarding any 
potential cardiovascular impact of exposure to engineered nanomaterial remains limited. 
Furthermore, the mechanisms, which underlie cardiovascular toxicity, are poorly defined or 
investigated.   This thesis sets out a study designed to evaluate the expansion of myocardial 
injury following acute occlusion and reperfusion after exposure to two sizes of silver 
nanoparticles (AgNP) capped with either polyvinylprryolidone (PVP) or citrate, and to 
understand the potential role of systemic inflammatory markers or electrical conductivity as 
underlying the cardiovascular toxicity.   
1.2. BACKGROUND 
1.2.1. SILVER NANOPARTICLES 
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In recent decades advances in materials sciences and engineering have yielded a new 
class of nano-sized materials. These nanomaterials have a size range of between 1 nm and 
100 nm in at least one dimension, and are characterized by high surface to mass ratio (81, 
105).  Of the various forms of engineered nanomaterials, silver nanoparticles (AgNP) have 
garnered much attention for potential uses in both industry and medicine. There has been long 
standing knowledge that silver exhibits innate antimicrobial properties (94) which have made 
AgNP an attractive particle for biomedical and consumer applications, including but not limited 
to: wound dressings silver impregnated catheters, vascular prosthetics, surgical mesh (136), 
clothing and undergarments, air filters, laundry detergents, toiletries, and water taps (22). 
However, despite the seemingly ubiquitous potential of AgNP, the toxicity of these engineered 
nanomaterials, particularly the cardiovascular toxicity, is poorly understood.  Furthermore, 
mechanisms by which AgNP may interact with biological interfaces through size or surface 
characteristics have yet to be fully elucidated.  
Toxicologically, AgNP have become the target of investigation due to the high reactivity 
of silver (Ag+) ions.   Ag+ ions bind to both sulfur and phosphate molecules (22), which may 
interrupt normal cellular membrane function as well as disrupt DNA and RNA binding (138).   
Silver  ion dissolution may be a key to understanding the underlying toxicological mechanisms 
of AgNP. Nanoparticle size may be another important factor in determining toxicological impact 
of AgNP exposure, particularly in metal derived nanomaterials.  The smaller the particle 
diameter, the more silver atoms are externalized, which may impact the degree of biological 
interactions by increasing the rate of ionic dissolution (102). Free Ag+ ions may contribute to 
the generation of oxidative stress as well as binding to sulfhydryl groups of proteins changing 
their function and activity (65).  Beyond the question of the contribution of Ag+ ion toxicity, 
interactions of AgNP in vivo also are proposed to play a crucial role in particle toxicity. Surface 
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charge of AgNP is thought to be a key factor in the toxicity associated with exposure to AgNP 
which may influence cellular membrane degradation or permeability (34). Surface oxidation of 
AgNP may also lead to oxidative stress (97) and interactions with macromolecules that may 
reflect altered signaling processes contributing to cardiovascular dysfunction following 
pulmonary exposure to AgNP (71).   
Inhalational exposure to aerosolized particles is a chief concern regarding the safety of 
engineered nanomaterials.  Aerosolization of particles may occur at several phases of AgNP 
manufacture and utilization. Inhalational exposure to AgNP is most likely to occur during 
particle synthesis, handling of dry powders, aerosolization of liquid suspensions, as well as the 
manufacture and machining of composites containing AgNP (102).  Exposure is also possible 
outside of the occupational exposure realm. Use of AgNP in consumer products such as 
disinfecting sprays or deodorants have the potential to directly aerosolize AgNP, which could 
lead to a direct pulmonary exposure to AgNP (102).    
1.2.2. PULMONARY EXPOSURE to PARTICULATE MATTER 
There has been wide investigation into the impact of exposure to various forms of 
particulate matter (PM) and their impact on the health of multiple organ systems. One of the 
primary areas of investigation has included pulmonary toxicity of PM. Pulmonary exposure 
serves as a primary route of human exposure to PM and pulmonary detriments from exposure 
to air pollution are well known. Particulate matter with a diameter of approximately < 100 nm 
has the ability to deeply infiltrate the lungs at the same time avoiding many mechanisms for 
clearance of larger foreign debris (66). The interaction with cells and tissues deep within the 
lungs may initiate a response leading to downstream cardiovascular detriments. Pulmonary 
exposure to PM has been demonstrated to not only induce a primary inflammatory response in 
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the lungs, but also prime the immune system to over-respond to an insult following PM 
exposure (81, 126).   Exposure to ultrafine particles had been shown to alter inflammatory 
responses through calcium signaling in pulmonary monocytes (33). Furthermore, the true 
impact of PM was unseen until secondary stimulation with thapsigargin whereby PM exposure 
induced a 2.5 fold increase in cytosolic calcium influx (33). The additional calcium may acting 
as a second messenger following PM exposure inducing heightened inflammatory responses.  
For example, A basophilic cell line exposed to AgNP was demonstrated to stimulate 
degranulation following AgNP induced calcium influx (137).  
 Murine exposure to PM induced inflammatory responses in the lungs of exposed 
animals, triggering ROS production (127). Increases in ROS may alter redox sensitive 
transcription of cytokines (44). Exposure to PM has been shown to induce increases in IL-6 
concentrations in BALF.  Localized cytokine secretion in the lungs has been theorized to lead 
to systemic inflammation (60). Furthermore, key pro-inflammatory mediators in the lungs, IL-
1β, IL-6, and TNFα also are known to have an impact on the heart.  Given the inflammatory 
response to PM in the lungs and the proximity and physiologic relationship between the heart 
and lungs, it seems likely that inflammatory responses in the lung may lead to effects in the 
heart and vasculature.  
1.2.3. THE HEART- LUNG CONNECTION 
It is very difficult to separate the lungs from the heart when evaluating pulmonary PM 
exposure and subsequent cardiovascular dysfunction. The heart and lungs are greatly 
interconnected in terms of anatomy and physiological function. There is a clear relationship 
between pulmonary exposure to a toxicant and cardiovascular compromise (10, 125).  Long 
term exposure to PM and air pollution drastically increase cardiovascular morbidity and 
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mortality in a dose-dependent manner (57).  Pulmonary exposure to diesel particles has been 
shown to induce a variety of cardiac effects. In one such study, ApoE-/- mice were placed on a 
western diet and then exposed to either diesel exhaust particles or saline. The mice exposed 
to diesel exhaust particles had significantly greater vascular plaque formation than mice 
exposed to only saline (68). In an experiment with heavy metal laden PM, pulmonary exposure 
exacerbated myocardial mitochondria injury (43). Furthermore, exposure to diesel has been 
shown to impact measures of autonomic control of the cardiovascular system (19). Despite 
well-known associations between pulmonary exposures and negative cardiac outcomes, the 
precise mechanisms remain unclear.  
In addition to systemic inflammation, translocation of particles out of the lungs to the 
cardiovascular system is another proposed mechanism of interaction between pulmonary 
exposures and cardiovascular toxicity. Ultrafine particles are inhaled deeply into the lungs are 
able to interface with pulmonary vasculature (60, 76).  Studies have demonstrated that both 
instillation and inhalation of nano sized materials result in a fraction of the nanomaterials 
crossing the blood alveolar barrier and entering systemic circulation (72, 78).  PM translocating 
from the lung would next reach the heart where the PM may act locally, stimulating direct 
cardiac toxicity however, this has yet to be demonstrated. There is a paucity of data regarding 
the degree to which particles are able to translocate from the lungs and to what organs, 
tissues, and cells are most susceptible to potential translocation.    
A third hypothesis regarding how pulmonary exposure impacts cardiovascular end 
points involves dysfunctional feedback in the ANS (77).  Exposure to PM has been shown to 
induce changes in heart rate variability, indicative of changes in autonomic balance (6, 19). In 
a study of healthy North Carolina State Highway patrol officers exposed to ultrafine particles 
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during a normal work shift, changes in heart rate variability as well as increased inflammatory 
blood markers were demonstrated (74). This study is of interest not only because it 
demonstrates the ability of pulmonary exposure to PM to impact normal cardiac physiology in 
healthy individuals, but demonstrates a link between: pulmonary exposure, autonomic function, 
inflammation and the cardiovascular system. In recent years our understanding of immunity 
has expanded to include reflex control of immune responses from the CNS. Pulmonary 
inflammation resulting from particulate exposure may increase vagal sensory input to the CNS 
resulting in increased cardiac vagal stimulation (74) and attenuate the inflammatory response 
to PM. ANS mediation of inflammation may also be impacted by adjustment to regulatory set 
points where prolonged decreased vagal outflow may induce a proinflammatory phenotype in 
the face of physiological insult (121).    The exact mechanism by which PM may modulate the 
ANS through pulmonary exposure is not well known. Particulate matter in the lung triggers 
activation of pulmonary C-fibers. Autonomic feedback from C-fibers can impact cardiac 
function by influencing vagal tone and may be a key component of the relationship between 
pulmonary exposures and cardiovascular outcomes (56, 66). 
1.2.5 MYOCARDIAL INFARCTION and ISCHEMIA/REPERFUSION INJURY 
The incidence of myocardial infarction is high, an estimated 1,255,000 new or recurrent 
events of myocardial infarction occur per year in the United States (100). The processes by 
which a vessel may become occluded are varied but often results from a blockage of the 
lumen of a coronary artery by, somewhat paradoxically, the repair response to a ruptured 
atherosclerotic plaque (107), whereby initial recruitment of platelets to the site of injury begins 
to block the lumen of a coronary artery and ultimately reduces or altogether stops blood flow to 
distal portions of the myocardium. Although the most common pathological mechanism for 
initiation of myocardial infarction, rupture of atherosclerotic plaques are not the only means of 
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inducing myocardial ischemia or infarction.  If oxygen (O2) demand outpaces O2 supply, such 
as during strenuous exercise (39), worsening cellular hypoxia can lead to ischemia. 
Furthermore, cardiac ischemia can be induced by coronary vasospasm (96). It is important to 
note that total luminal occlusion of a coronary artery is not required to induce infarction, as 
decreased coronary flow may result in inadequate O2 distribution to cardiac tissue, resulting in 
ischemia and ultimately cardiomyocyte death. 
The cellular mechanisms that ultimately lead to cardiomyocyte death are strongly tied to 
hypoxia. During ischemia adequate O2 can no longer be delivered to tissues. The heart is an 
organ with high metabolic demand; as such, delivery of O2 to the myocardium via the coronary 
arteries in support of normal cardiac function is crucial (16). Occlusion of one or more coronary 
arteries leads to ischemia in areas distal to the blockage, whereby metabolism is 
compromised. The inability to generate adenosine triphosphate (ATP) via oxidative 
phosphorylation causes a shift to anaerobic glycolysis (17). Anaerobic glycolysis increases 
intracellular H+ ion concentration inducing acidosis that then disturbs the Na+/H+ exchanger. 
ATP depletion inactivates Na+ /K+ ATPase. The combined effect results in Na+ overload, Na+-
Ca++ exchanger attempts to compensate for the Na+ overload by pumping Ca++ into the 
cytoplasm, however the Ca++ overload induces myocardial contracture and cell death (71). The 
cytosolic oversaturation with Na+ or Ca++ results in an osmotic force resulting in cellular edema 
(17). Activation of phospholipases by intracellular calcium degrades cardiomyocyte cell 
membranes (17, 84) contributing to cell death and myocardial infarction.  
In order to restore normal cardiac function it is imperative to restore coronary blood flow. 
Clinically, blood flow can be restored through medical interventions such as thrombolytic 
therapy or percutaneous coronary intervention (135), but the restoration of blood flow, known 
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as  reperfusion, can also  result in further myocardial injury, known as reperfusion injury.  
Reperfusion injury is a broad term that encompasses several processes including arrhythmia, 
myocardial stunning, and microvascular injury leading to no -reflow phenomenon (17, 91). The 
mechanisms of reperfusion injury are diverse, and in many respects mirror processes 
witnessed in ischemic injury.   
Reactive oxygen species (ROS) are thought to play a key role in mediating reperfusion 
injury (52).  The surge of O2 associated with reperfusion generates superoxide anion or 
peroxynitrate by cardiomyocyte mitochondria (123).  The impact of ROS on reperfusion injury 
is varied and thought to involve triggering at least one of the following: protein kinases and 
various genomic pathways (91, 84, 6), peroxidation of lipid membranes diminishing cell 
membrane integrity (70),  triggering apoptosis (15, 16, 30), and dysfunction in Ca++ handling 
(37).   
 Calcium  handling in reperfusion injury is further influenced by influxes in Na+.  Much 
like in ischemia, exchange of Na+ for Ca++ leads to high cytosolic Ca++. The overload of 
calcium leads to rigor type contracture, where high levels of Ca++ leads to excessive activation 
of myocardial contraction. Rigor type contraction contributes to the development of myocardial 
dysfunction and induces apoptosis (30).  Additionally, fluctuations in Ca++ from the 
sarcoplasmic reticulum stimulate opening of the mPTP (1, 32).  Once the mPTP opens, the  
proton gradient required for synthesis of ATP rapidly dissipates and H2O is able to flood into 
mitochondria, causing mitochondrial swelling and rupture and triggering apoptosis as well as 
necrosis (85).  Production of Ang-II by RAS induces increases in intracellular Ca++ of 
cardiomyocytes and smooth muscle, impairing diastolic function and inducing coronary 
vasoconstriction, respectively (30). 
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Leukocyte trafficking is another key component of reperfusion injury that occurs shortly 
after return of blood flow (30). During reperfusion neutrophils move to areas of ischemia in 
order to phagocytose dead tissue, releasing cytokines to further mediate the immune response 
(115).  The factors secreted by neutrophils may be damaging to viable tissue and include 
ROS, cytokines and chemokines (51).  Neutrophils collect in post-capillary venules causing 
obstruction and contribute to microvascular dysfunction (51,106). It is thought that 
microvascular dysfunction mediates no-reflow phenomenon associated with reperfusion injury 
(93). Platelets recruited to sites of injury also may contribute to reperfusion injury and 
microvascular dysfunction by secreting vasoactive thromboxane A2 and 5-HT.  Monocytes 
infiltrating the zone of infarction following reperfusion further augmenting the inflammatory 
response to ischemia and reperfusion by releasing proteases capable of infarct expansion 
through proteolysis (43). 
1.2.6 CYTOKINE MEDIATORS OF MYOCARDIAL DYSFUNCTION  
There is a strong association between elevated levels of circulating cytokines and 
cardiovascular disease. In humans with coronary artery disease (CAD), it has been shown that 
elevated serum concentrations of IL-1β, TNFα, and IL-8 are present during events of unstable 
angina (87). IL-1β and TNFα, in addition to IL-18 are responsible for enhanced surface 
expression of selectins, VCAM-1 and ICAM-1 (62, 53), which indicate endothelial activation 
due to inflammation (132) and which may play a role in vascular changes associated with 
particle exposure and no-reflow phenomenon (62, 67).  IL-1 family cytokines, including IL-18, 
have been shown to contribute to LV dysfunction post-MI (86, 130). The dose-dependent 
impairment of myocardial dysfunction is synergistic with cardio depression caused by TNFα 
(63, 132). Interleukin-18 activates T-cells in response to interferon (INF)y which then induces 
release of IL-6.  Interleukin-6 a prototypical cytokine and key mediator of acute phase 
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response as well as stimulated release of TNFα. Elevated concentrations of circulating 
proinflammatory cytokines, such as TNFα and IL-6 by activation of innate immune cells has 
been associated with a worsening of heart failure (19, 73, 103).  During ischemia, IL-6 and 
TNFα are released into ischemic and border zone areas of the heart as a response to 
myocardial stretch and stress (80).  IL-6 is associated with cardiac hypertrophy, and 
myocardial wasting and dysfunction (132). Acute coronary syndrome also is associated with a 
rise in plasma concentrations of IL-6 and IL-2 (35, 42). IL-2 is a proinflammatory cytokine key 
to T cell differentiation promoting T helper (Th)1 and Th2  while inhibiting Th17 and T follicular 
helper cells (91). Infusion of exogenous IL-2 has been shown to induce heart failure and 
myocarditis (36, 104).   Considering the overall impact on cardiovascular dysfunction directly 
attributed to pro-inflammatory cytokines, in addition to secondary damage from leukocyte 
recruitment, cytokines may play a role in mediating cardiovascular dysfunction and expansion 
of I/R injury. 
1.3. HYPOTHESIS and AIMS 
There is strong evidence that exposure to PM can exacerbate cardiovascular disease. 
The mechanisms by which pulmonary exposure to PM can mediate cardiac injury are unclear. 
We hypothesize that intratracheal (IT) instillation of AgNP induces a proinflammatory response 
and autonomic dysfunction that augments cardiac I/R injury for up to seven days following 
exposure. 
1.3.1. AIM 1:  
Determine the extent of cardiac I/R injury on SD rats 24 hours and 168 hours after IT 
instillation of AgNP. 
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1.3.2. AIM 2:   
Compare the impact of IT instillation of AgNP on electrical and autonomic dysfunction in 
SD Rats prior to and during I/R injury with ECG.   
1.3.3. AIM 3:   
Profile the circulating cytokines in serum: 0, 1, 3, 6, 24, 48, 72, 168 hours and following 
I/R injury after IT exposure to AgNP to determine the inflammatory impact of particle exposure. 
  
CHAPTER 2 
METHODS and MATERIALS 
2.1. EXPEREMENTAL DESIGN 
In order to determine the impact of pulmonary exposure to silver nanoparticles (AgNP) we 
performed intratracheal (IT) instillation of male Sprague-Dawley (SD) rats with 20 nm or 110 
nm AgNP capped with PVP or citrate, or a respective PVP or citrate vehicle. By evaluating two 
sizes of AgNP as well as capping agents we are able to begin to define the physiochemical 
properties of the materials that impact cardiovascular toxicity (40,3). An additional cohort of 
animals was instilled with silver acetate AgAc in order to determine the contribution of ionic 
silver to cardiac injury.  
 Twenty four or 168 hours post IT instillation rats underwent a 20 minute occlusion of the 
LAD followed by 2 hours of reperfusion.  Following reperfusion the heart were stained with 
TTC and analyzed for the extent of myocardial infarction (MI)(47). (Aim 1) ECG was monitored 
for a baseline period then throughout occlusion and reperfusion in order to evaluate the 
potential contribution of autonomic dysfunction to I/R injury by measuring heart rate (HR) (57, 
132), PR interval, and QT interval (21). (Aim 2) Blood was collected prior to instillation and 1, 
3, 6, 24, 48, 72 and 168 hours after IT instillation to examine concentrations of circulating 
cytokines and chemokines over time. A final blood sample following I/R injury was collected to 
examine differences in circulating cytokines released in response to cardiac I/R injury following 
exposure to AgNP. (Aim 3) 
2.2. ANIMALS 
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Male (SD) rats between the age of 51 and 54 days and weighing between 201-225 grams 
were purchased from Charles River Laboratory (Raleigh, NC, USA). Rats were housed two per 
cage under 12 hour light/dark cycles. Standard rat chow and water were provided ad libidum. 
All animals were allowed a 1 week acclimatization period in the East Carolina University (ECU) 
Department of Comparative Medicine vivarium prior to any experimentation.  Animals were 
randomly assigned to 10 experimental groups: 1 or 7 day naïve, small PVP vehicle, small 
AgNp, large PVP vehicle, and large AgNp, citrate, small citrate, and large citrate. A second 
cohort of SD rats was randomized into 3 groups and received 1 mg/mL, 0.01 mg/mL, or 0.001 
mg/mL AgAc.   ECU Institutional Animal Care and Use Committee approved all animal 
handling and experimental procedures. 
2.3. NANOMATERIAL and VEHICLES 
For the purposes of investigation both PVP and Citrate coated AgNP were used for instillation. 
To test toxicity of exposure to ionic silver AgAc was obtained as a dry powder from RTI 
International (Research Triangle Park, NC).  20 nm and 110 nm AgNp were manufactured and 
provided to the investigators by nanoComposix (San Diego, CA) through the NCNHIR U19 
Consortium funded through NIEHS.  The prepared nanomaterials were characterized by the 
National Characterization Laboratory associated with the National Cancer Institute.  
2.3.1 PVP CAPPED AgNP 
20 nm and 110 nm AgNp were capped with polyvinylpyrrolidone (PVP) to prevent particulate 
agglomeration. Each AgNp size was evaluated for hydrodynamic diameter utilizing dynamic 
light scattering (DLS), as well as transmission electron microscopy (TEM) for determining core 
diameter. Zeta potential analysis was utilized for determination of surface charge. Silver 
concentration was determined by inductively coupled plasma mass spectrometry (ICP-MS). 
 
 
2 
 
Endotoxin levels were also characterized and found to be below acceptable limits. Table 2.1 
provides characterization of AgNP.  Aliquots of PVP capped AgNP showed plating on their 
containers, which may indicate a breakdown of the nanomaterial. More frequent 
characterization of nanomaterials may be necessary once stored to ensure structural stability.   
2.3.2 PVP VEHICLES 
The vehicles for PVP control groups were created by adding sterile saline to a 10 or 40 kDa 
PVP dry powder to yield a 1.4% PVP/saline solution. The 10 kDa PVP/saline mixture was used 
as the vehicle control for the 20 nm AgNp and the 40 kDa PVP/saline mixture was used for the 
110 nm AgNp. 
2.3.3 CITRATE CAPPED AgNP 
20 nm and 110 nm AgNp were coated with citrate to prevent particulate agglomeration.  Each 
AgNp size was evaluated for hydrodynamic diameter by DLS as well as TEM determined the 
core diameter. Zeta potential analysis was utilized for determination of surface charge. Silver 
concentration was determined ICP-MS. Endotoxin levels were also characterized and found to 
be below acceptable limits.  Table 2.1 provides characterization of AgNP.   
2.3.4 CITRATE VEHICLE 
The vehicle control for citrate AgNP was created with a 2 mM solution of sodium citrate 
dissolved in deionized H20. Unlike PVP capped AgNP groups, one citrate vehicle was 
sufficient for both 20 nm and 110 nm particles. 
2.3.4 AgAc 
Silver Acetate was provided by RTI International (Research Triangle Park, NC) as purchased 
from Sigma-Aldrich (St. Louis, MO, USA). 1.62 mg of AgAc was dissolved in sterile H20 to 
create an ionic silver concentration of 1 mg/mL.  Dilutions were made from an aliquot of the 1 
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mg/mL AgAc to yield 0.1 mg/mL AgAc and 0.01 mg/mL AgAc. All sliver solutions and dry AgAc 
were stored at 4°C and kept from light.  
2.4. AgNP PREPARATION, DOSING, and INTRATRACHEAL INSTILLATION 
AgNP aliquots were cup-horn sonicated for 30 seconds at 50% amplitude (Misonix Model 
1510r-MTH, Branson Ultrasonics Corp. Danbury, CT). Aliquots were vortexed prior to 
instillation for 30 seconds. Rats were anesthetized by inhalation of a 50:50 isoflurane 
propylene-glycol mixture in an induction chamber. Once an adequate plane of anesthesia had 
been achieved and assessed by physical examination, the rat was moved from the induction 
chamber and suspended by the frontal incisors on a inclined board. The tongue of the rat was 
anteriorly displaced with padded forceps and a pipette tip was placed into the laryngopharynx, 
just superior to the glottis. 200 uL of AgNP, AgAc, or vehicle was dispensed into the glottal 
opening and the rat was stimulated to breathe while securing the tongue with forceps, ensuring 
pulmonary aspiration.   Following instillation the rats were returned to their home cage and 
monitored until they resumed normal grooming behavior.  
2.5. SERIAL BLOOD COLLECTION 
Rats were anesthetized by inhalation of 2-3% isoflurane, dispersed in medical grade oxygen, 
until an adequate plane of anesthesia had been achieved and assessed by physical 
examination. The rats were transferred to a nose only inhalation system to deliver 1% 
isoflurane dispersed in medical grade oxygen to ensure maintenance of anesthesia throughout 
blood collection. The rats were place in a lateral recumbent position on a heating pad. The tail 
was prepared for venipuncture by cleaning with a sterile 70% isopropyl saturated prep pad. 
Location of the lateral tail vein was obtained by visual inspection.  Venipuncture was achieved 
with a BD Vacutainer 25 g needle collection set (Becton, Dickinson, and Company, Franklin 
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Lakes, NJ). Blood from the tail was collected into BD microtainter serum separator tubes 
(Becton, Dickinson, and Company, Franklin Lakes, NJ). Approximately 200-300 µL was 
collected at each time point. Time points for collection were: prior to AgNp exposure and 1, 3, 
24, and 168 hours following exposure. Following the ischemia-reperfusion surgery a final blood 
sample was obtained from the inferior vena cava. All samples were allowed to sit at room 
temperature for approximately 30 minutes before being centrifuged at 2000 rcf at room 
temperature for 2 minutes.  Serum supernatant was removed from the sample, snap frozen in 
liquid N2 and stored at - 80 °C. 
2.6. CARDIAC ISCHEMIA/REPERFUSION and QUANTIFICATION of INFARCT SIZE 
Twenty-four or 168 hours following IT instillation rats were anesthetized with an intramuscular 
injection of ketamine/xylazine (90/10 mg/kg, respectively). Anesthesia was maintained 
throughout the procedure with supplemental injections of ketamine/xylazine. Body temperature 
was maintained at 37°C with a heating pad and TC-1000 Temperature Controller (CWE, Inc., 
Ardmore, PA).  Once an adequate plane of anesthesia was achieved the rats were intubated 
via tracheostomy with a 16 gauge angiocatheter.  Rats were ventilated with fraction of inspired 
oxygen (FiO2) of 1 via an Inspira Advanced Safety Ventilator (Harvard Apparatus, Holliston, 
MA) with a 3 mL tidal volume at 81 breaths per minute.  
Each animal was allowed at least 15 minutes of equilibration prior to any baseline collection 
prior to ischemic manipulation.  Following the baseline period the heart was visualized by an 
anterolateral partial sternotomy.  The LAD was visualized and occluded with 6-0 prolene suture 
and PE 90 with a flared end as a reversible tourniquet. The tourniquet was secured in place for 
a 20 minute period of ischemia by Kelly hemostatic forceps.  Successful occlusion of the LAD 
was confirmed by: A.) blanching of the myocardium distal to the occlusion, B.) myocardial 
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dyskinesia, and C.) ECG changes (Fig. 2.1).  Following 20 minutes of ischemia the reversible 
tourniquets was released allowing two hours of reperfusion.    
Following reperfusion the rat was exsanguinated by transection of the inferior vena cava. The 
descending thoracic aorta was then cannulated with PE 90 and advanced to the coronary 
ostia.  The heart was flushed with approximately 5 mL 0.09% normal saline followed by 5 mL 
of 0.25% TTC (Sigma-Aldrich, St. Louis, MO) to determine viable from infarcted tissue. 
Following infusion of TTC the LAD is re-occluded and the heart is infused with 1% Evans blue 
dye in order to demarcate the remote myocardium.  Following Evans blue infusion the heart 
was excised and sliced into approximate 1mm sections distal to the occlusion. (Fig. 2.2) The 
slices were sandwiched between two glass slides and both sides were digitally photographed.  
Image J was obtained from the National Institutes of Health was used to determine the area of 
the left ventricle, area at risk, and area of infarction.   
2.7. ECG MONITORING and ANALYSIS  
ECG recordings during the surgical procedure were obtained by PowerLab 8/35 data 
acquisition interface (AD Instruments, Colorado Springs, CO, USA), Animal Bio Amp 
(ADInstruments), and LabChart 7 Pro (ADInstruments). Anesthetized rats were placed supine 
and four total needle electrodes were inserted subcutaneously into one in each limb and 
secured with surgical tape. Electrode placement provided lead II for analysis. Each animal was 
allowed at least 15 minutes of baseline rhythm collection prior to ischemic manipulation.  
Intervals and segments were measured at several time points throughout the baseline period 
and surgical procedure. At each time point, 10 seconds of ECG recording were analyzed for 
average: HR, QT Interval (with Bazette’s correction for heart rate), and PR interval. For each 
10 second period, ectopic beats or sections of artifact were excluded from analysis. In addition, 
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in order to reduce the overall number animals required for experimentation, rhythm conversion 
was attempted when the duration of VT or VF was deemed life threatening. 
2.8. QUANTIFICATION of SERUM CYTOKINES 
Concentrations of serum: IL -1β, IL-2, IL-5, IL-6, IL-10, IL-13, IL-18, MCP-1, G-CSF, GM-CSF, 
IFNγ, MCP-1, MIP-1α, RANTES, and TNFα were measured at selected time points with a 7-
plex Milliplex MAP Cytokine/Chemokine Panel and Immunoassay (EMD Millipore, Billerica, 
MA) according to the manufacturer’s instructions. The naïve and PVP capped AgNP and 
respective vehicle groups were run on a Luminex 200 (Luminex, Austin, TX). Citrate capped 
AgNP and vehicle groups were run on a MagPix system (Luminex, Austin, TX)  and all results 
were reported and analyzed by Milliplex Analyst version 5.1(EMD Millipore, Billerica, MA). 
2.9. STATISTICAL ANALYSIS 
All data are presented as mean value ± SEM.  a P-value of < 0.05 indicated statistical 
significance unless otherwise noted. GraphPad Prism software version 6 (LaJolla, CA) was 
used for the purposes of statistical analysis and graphing. Cardiac I/R data were compared by 
one-way ANOVA with Bonferroni’s post-hoc test. Differences between time and particle 
capping were performed by t-test.  Group size was calculated based on power analysis of 
cardiac I/R experiments. ECG data was analyzed by one-way ANOVA with Tukey post-hoc 
test. Cytokines were compared to their respective vehicle by t-test.  
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Table 2.1:  NCL particle characterization data for PVP and citrate capped AgNP. 
Hydrodynamic size reported was determined from Z-average. Data are as presented as a 
mean ± SEM of replicates.  
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 PVP Capped AgNP Citrate Capped AgNP 
20 nm 110 nm 20 nm 110 nm 
Hydrodynamic Size (nm) 26.00 ± 0.089 112.3 ± 0.149 23.98 ± 0.0477 104.2 ± 0.120 
Core Diameter (nm) 20.95 ± 0.311 114.2 ± 1.421 20.28 ± 0.229 111.3 ± 1.970 
Zeta Potential (mV) - 37.12 ± 1.136 - 25.92 ± 1.237 - 48.50 ± 2.059 - 43.02 ± 1.472 
Silver Concentration (mg/g) 1.090 ± 0.001 1.101 ± 0.003 1.105 ± 0.007 0.980 ± 0.014 
Endotoxin Concentration (EU/mL) 1.133 ± .291 <0.5 ± 0 <0.5 ± 0 <0.5 ± 0 
 
 
9 
 
 
Figure 2.1: ECG changes indicative of positive occlusion of the LAD.  Panel A contains a 
representative sample of ECG recording prior to occlusion of the LAD. Panel B displays 
classical post-occlusion ST segment elevation morphology.  Panel C illustrates a high level of 
myocardial ectopy (arrows) resulting from myocardial ischemia induced by ligation of the LAD. 
Presence of ST segment elevation and myocardial ectopy indicate proper occlusion of the 
LAD.    
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Figure 2.2: Representative naive (panel A) and particle exposed (panel B) transverse 
myocardium slices having undergone I/R protocol. Following I/R protocol panel B. shows a 
greater area of infarct within the area at risk (areas appear white or unstained). 1 indicates 
Evans blue counterstain to demarcate remote myocardium uninvolved in the ischemic event. 2 
identifies TTC positive staining indicating the myocardial area at risk for ischemic injury that 
remained viable. 3 indicate TTC negative staining denoting areas of myocardial subject to 
infarction. Left ventricle (LV) and right ventricle (RV) are indicated. 
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CHAPTER 3 
EXPANSION OF CARDIAC I/R INJURY FOLLOWING INTRATRACHEAL 
EXPOSURE to AgNP. 
3.1 INTRODUCTION 
Exposure to particulate matter (PM) has been linked with cardiovascular disease and 
dysfunction. Exposure to air pollution has been associated with an acute rise in incidence of 
myocardial infarction (MI) (10). Pulmonary exposure to diesel particulate has been implicated 
in expansion of ischemia reperfusion (I/R) injury in male Wistar rats as early as 6 hours 
following PM exposure (29, 99, 120). The apparent cardiovascular toxicity of pollution 
associated PM has raised concerns regarding the cardiovascular toxicity of engineered 
nanomaterials. In a murine model pulmonary instillation of MWCNT resulted in persistent 
expansion of I/R injury up to 28 days following exposure (124).  Likewise, intratracheal (IT) 
instillation of C60 fullerenes resulted in expansion of cardiac I/R injury in SD rats 24 hours 
following pulmonary exposure (119). Given the apparent ability of a range of PM to exacerbate 
I/R injury (64, 109), this thesis investigated the impact of pulmonary exposure to AgNP on 
cardiac I/R injury 24 hours and 7 days following an IT instillation of 200 gs of AgNP. We 
hypothesized that pulmonary exposure to AgNP would result in expansion of cardiac I/R injury 
24 hours and 7 days post instillation. 
3.2. RESULTS  
3.2.1 AgNP EXPANDS CARDIAC I/R INJURY 24 HOURS FOLLOWING IT INSTILLATION 
Ventricular heart segments were analyzed following a protocol of 20 minutes of 
ischemia and 2 hours of reperfusion following IT exposure to 200 μgs of 20 nm or 110 nm 
citrate or PVP capped AgNP.  Instillation of both 20 nm and 110 nm PVP capped AgNP 
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resulted in a significantly elevated percentage of infarcted myocardium within an area at risk, 
41.65 ± 2.05 % and 36.82 ± 2.75 %, respectively  when compared to naïve, 22.30 ± 1.57 % or 
corresponding vehicles, small PVP, 21.59 ± 1.27  and large PVP, 23.65 ± 2.43 (Figure 3.1).  
Similarly, both sizes of citrate capped AgNP induced expansion of MI  20 nm, 37.48 ± 2.61 % 
and 100 nm, 30.51 ± 1.58 % as compared to citrate vehicle, 24.05 ± 1.28 % and naïve 24 
hours following IT instillation (Figure 3.2). At 24 hours no differences exist in the extent of 
myocardial infraction between particles sizes within a capping group, however there was a 
difference in the extent of I/R injury between 20nm PVP capped and 110nm citrate capped 
AgNP. At 24 hours following IT instillation, 110 nm citrate capped AgNP induced less 
myocardial injury than the 20 nm PVP capped AgNP.    
3.2.2. AgNP EXPANDS CARDIAC I/R INJURY 168 HOURS FOLLOWING IT 
INSTALLATION 
IT instillation of PVP capped AgNP demonstrated persistent I/R injury 7 days post 
exposure, 37.79 ± 2.74 % and 42.06 ± 4.71 %, respectively compared to naïve, 16.99 ± 0.64 
% or small PVP 23.27 ± 0.89 %, and large PVP, 27.21 ± 2.20 % (Figure 3.3).  There was no 
difference in the extent of cardiac injury between 24 and 168 hours post instillation in rats 
exposed to PVP capped AgNP (Figures 3.1 and 3.3).  Citrate capped AgNP demonstrate the 
ability to expand myocardial infarction 7 days following IT instillation: 20 nm, 36.85 ± 1.39 % 
and 110nm 28.30 ± 2.24 % compared to citrate vehicle 20.83 ± 1.28 (Figure 3.4). The 
expansion of the I/R Injury at 168 hours post instillation was greater with the 20nm citrate 
capped AgNP than that of the 110 nm citrate capped AgNP.  168 hours following IT exposure 
to 110 nm AgNP resulted in a significantly smaller I/R injury with in the 110 nm citrate capped 
AgNP as compared to the I/R injury associated with 110 nm PVP capped AgNP. 
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3.2.3. IT INSTILLATION of AgAc RESULTS in EXACERBATION of I/R INJURY 
Dose response to administration of 200 l of 0.01 mg/mL, 0.1 mg/mL, and 1 mg/mL 
AgAc demonstrated an increase in I/R injury 24 hours following IT instillation (Fig 3.5). The 
lowest concentration AgAc administered did not result in any statistical increase in infarction 
percent 21.62 ± 1.9 % compared to the naïve group 16.99 ± 0.64 %. The highest concentration 
of AgAc resulted in a mean injury of 37.55 ± 4.15 % and the median concentration of AgAc 
resulted in 28.20 ± 0.17 % of the area at risk infracting. 
3.2.4 IT INSTILLATION of 1mg/mL AgAc DECREASES POST OCCLUSION SURVIVAL      
Sprague Dawley rats IT instilled with 1mg/mL AgAc exhibited higher post occlusion 
mortality than any other group (Fig 3.6).   Intratracheal instillation of 1mg/mL AgAc resulted in 
premature mortality for 3 of the 4 rats within the cohort, dying only 5, 15, and 30 minutes into 
reperfusion. No other experimental group experienced such a profound mortality rate 
associated with the ischemia reperfusion protocol. 
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Figure 3.1: Male SD rats exposed to IT instillation of 20nm or 110 nm AgNP, or PVP vehicle.  
I/R injury is expanded 24 hours following IT exposure to AgNP. Statistical significance, P < 
0.05 determined by one-way ANOVA with Bonferonni post hoc test.  a significant versus naïve, 
b significant vs vehicle.  n= 3-4 
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Figure 3.2:  Male SD rats exposed to IT instillation of 20nm or 110 nm AgNP, or citrate 
vehicle.  I/R injury is expanded 24 hours following IT exposure to AgNP. Statistical 
significance, P < 0.05 determined by one-way ANOVA with Bonferonni post hoc test.  a 
significant versus naïve, b significant vs vehicle n= 3-4. 
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Figure 3.3:  Male SD rats exposed to IT instillation of 20nm or 110 nm AgNP, or PVP vehicle.  
I/R injury is expanded 168 hours following IT exposure to AgNP. Statistical significance, P < 
0.05 determined by one-way ANOVA with Bonferonni post hoc test.  a significant versus naïve, 
b significant vs vehicle.  n= 3-4 
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Figure 3.4:  Male SD rats exposed to IT instillation of 20nm or 110 nm AgNP, or citrate 
vehicle.  I/R injury is expanded 168 hours following IT exposure to AgNP. Statistical 
significance, P < 0.05 determined by one-way ANOVA with Bonferonni post hoc test.  a 
significant versus naïve, b significant vs vehicle, c significant vs other particle size. n= 3-4 
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Figure 3.5:  Male SD rats exposed to IT instillation of 0.01 mg/mL, 0.1 mg/mL, or 1 mg/mL 
AgAc.  I/R injury is expanded 24 hours following IT exposure to the two highest concentrations 
of AgAc. Statistical significance, P < 0.05 determined by one-way ANOVA with Bonferonni post 
hoc test.  a significant versus naïve, b significant vs AgAc concentration.  n= 3-4 
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Figure 3.6: Survival plot of all groups demonstrates animal survival time into reperfusion. Only 
animals from the group instilled with the highest concentration of AgAc failed to survive to the 
end of the designated reperfusion protocol, with deaths at 5, 15, and 30 minutes into 
reperfusion. n= 3-4   
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3.3. DISCUSSION 
These data reveal that pulmonary exposure to AgNP results in exacerbation of 
myocardial infarction following a 20 minute period of ischemia and two hours of reperfusion in 
Sprague-Dawley-Rats up to 7 days following instillation. Although there are no statistical 
differences between the 20 nm and 100 nm AgNP I/R Injuries at 24 hours the slight differences 
measured are suggestive that capping agents may influence the downstream toxicity 
associated with a pulmonary AgNP exposure (114). The apparent difference in I/R injury 
observed at 7 days post instillation may be mediated by an interaction of particle size as well 
as capping agents. Twenty four hours following IT exposure, both size particles in both 
capping agents have a similar impact on expansion of I/R injury. These findings are congruent 
with other studies evaluating expansion of cardiac I/R injury following pulmonary exposure to 
various engineered nanomaterials in rats and mice (13, 14, 118). At 7 days post exposure a 
trend begins to develop where exposure to 20 nm AgNP maintains an augmented I/R injury 
independent of capping agent. However by 7 days post exposure, the impact of 110 nm AgNP 
on I/R injury appears to be capping agent dependent.  At 7 days post exposure PVP capped 
110nm AgNP results in an expansion of I/R injury that appears to be slightly larger than that 
seen at 24 hours, whereas extent of I/R injury with citrate capped AgNP is lower. It appears 
that  any initial insult to the lungs by pulmonary exposure to AgNP induces  expansion of MI 
independent of particle size or capping.  However, unique biophysical interactions between 
particle sizes and capping agents may trigger unique downstream pathways of toxicity capable 
of inducing differential responses at later time points (22).  
A secondary question can be raised regarding AgNP and potential cardiovascular 
toxicity:  What, if any, contribution do silver ions have in the exacerbated myocardial I/R injury? 
In order to address that question, male SD rats were instilled with 1 mg/mL, 0.1 mg/mL, or 0.01 
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mg/mL concentrations of AgAc, a silver salt that dissociated to form Ag+ in an aqueous solution. 
These concentrations represent a range of potential silver ion dissolution from the 
nanoparticles in the lungs ranging from 100% dissolution to 1%.   Reports from the NIH 
Centers for Nanotechnology Health Implications Research Consortium meetings suggest that 
the dissolution rate form theses nanomaterials in in vitro settings can range from 1- 30% 
dependent on the particle size and the initial suspension concentration. Comparing I/R injury 
expansion from AgAc to AgNP we observe similar levels of injury expansion at the highest 
concentration of AgAc as induced by AgNP. However, 1 mg/mL AgAc represents a higher than 
expected in vivo dissolution rate. Instillation of 0.1 mg/mL AgAc also induced I/R injury 
equivalent to all but 20 nm PVP capped AgNP. These data allow us to suggest, based on 
comparisons of AgNP to AgAc concentration dependent I/R injury, particle dissolution rates are 
likely greater than 10% within the first 24 hours.   The in vitro dissolution rate is dependent on 
concentration, so it may be the expansion of I/R injury at 24 hours post exposure is associated 
with processes effected by the rate of dissolution of Ag+. Alternatively, particle size and 
capping agent may impact the concentration of silver ions able to interact with cells and tissue 
in vivo.  It is apparent that Ag+ ions are at least partially responsible for the cardiovascular 
toxicity of AgNP due their concentration dependent ability to expand I/R injury 24 hours post IT 
instillation.  It may be that Ag+ ions, alone, that are more detrimental than AgNP as evidenced 
by the high intraoperative mortality only seen in the 1mg/mL AgAc cohort.   
  
CHAPTER 4 
ELECTRICAL and AUTONOMIC RESPONSE to IT INSTILLATION of AgNP 
4.1 INTRODUCTION 
 Previous studies have demonstrated the ability for pulmonary exposure to particulate 
matter (PM) to impact autonomic function (19, 21).  In order to determine the impact of 
pulmonary exposure to AgNP on cardiac autonomic function we analyzed electrocardiogram 
(ECG) data recorded during the ischemia reperfusion (I/R) experimental protocol. In order to 
measure the potential influence of AgNP exposure on autonomic function we evaluated: heart 
rate (HR), PR interval, and corrected QT interval (QTc). Changes in HR may indicate whether 
AgNP exposure results in changes to parasympathetic and sympathetic balance and 
regulation of HR. PR interval is the ECG surface reading of atrial depolarization as well as 
conduction through the atrioventricular (AV) node interval (75) which are subject to control of 
the autonomic nervous system (ANS) whereby increased vagal tone slows AV conduction and 
increases PR interval.  QT interval with Bazett’s correction for HR is used to determine the 
duration of ventricular action potential via surface ECG (101, 140). Additionally, prolongation of 
QT interval beyond the compensatory influence of autonomic tone places the heart at 
significant risk for ventricular arrhythmias which may contribute to the development of ischemia 
as well as sudden cardiac death (38).        
4.2 RESULTS 
4.2.1 AgNP SIZE AND CAPPING DO NOT IMPACT HEART RATE 7 DAYS POST 
EXPOSURE 
In order to determine the potential impact of IT instillation of AgNP seven days following 
exposure on cardiac autonomic function we evaluated the HR of male SD rats by sampling a 
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baseline period of 15 minutes for 10 seconds at 1, 5, 10, and 15 minutes prior to ischemic 
manipulation.  Exposure to PVP capped AgNP had no impact on mean baseline HR (Fig 4.1). 
IT instillation of citrate capped AgNP also resulted in no differences in HR within baseline (Fig 
4.2). Likewise, there were no differences in HR following occlusion of the LAD or reperfusion in 
either PVP (Fig 4.1) or citrate (Fig 4.2) capped groups.  
4.2.3 AgNP DOES NOT IMPACT QTc 7 DAYS POST EXPOSURE 
 Analysis of ECG revealed no differences in mean QTc between AgNPs, naïve, or 
controls, during baseline, ischemia, reperfusion for PVP capped AgNP (Fig 4.3). Citrated 
capped AgNP also demonstrated no differences in mean QTc during baseline, ischemia, and 
reperfusion (Fig 4.4).  
4.2.2 AgNP SIZE and CAPPING DIFFERENTALLY IMPACT PR INTETERVAL. 
Intratracheal instillation of PVP capped AgNP does not significantly alter baseline or ischemic 
PR interval at 7 days following exposure (Fig. 4.3). Likewise, IT instillation of citrate capped 
AgNP resulted in no differences in baseline or ischemic PR interval compared to vehicle or 
naïve at 7 days post exposure (Fig 4.4). Mean reperfusion PR interval was longer in 20 nm 
PVP capped AgNP, 0.052 ± 0.002 seconds, than SPVP vehicle, 0.045 ± 0.002 seconds, but 
not significantly different than naïve, 0.053  ± 0.001 seconds. 110 nm PVP capped AgNP was 
not different from LPVP vehicle or naïve. (Fig. 4.5) PR interval was decreased in 20nm citrate 
capped AgNP, 0.048 ± .001, compared to citrate vehicle, 0.055 ± 0.002 seconds, but not 
naive, 0.053 ± 0.001 seconds, 110 nm AgNP was not statistically different from naïve or 
vehicle (Fig 4.6).   
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Figure 4.1: Heart rates for male SD rats exposed to PVP capped AgNP 7 days prior to 
assessment. Mean values displayed based on a 10 second sample at: 1, 5, 10, 15 minutes 
into baseline (A) and occlusion (B). 10 second samples were taken at: 1, 5, 10, 15, 25, 30, 45, 
60, 75, 90, 105 and 120 minutes during reperfusion (C). No differences in HR exist.  P < 0.05 
determined by two-way ANOVA with Tukey post hoc test, n=3-4. 
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 Figure 4.2: Heart rates for male SD rats exposed to citrate capped AgNP 7 days prior to 
assessment. Mean values displayed based on a 10 second sample at: 1, 5, 10, 15 minutes 
into baseline (A) and occlusion (B). 10 second samples were taken at: 1, 5, 10, 15, 25, 30, 45, 
60, 75, 90, 105 and 120 minutes during reperfusion (C).  No differences in HR exist.  P < 0.05 
determined by two-way ANOVA with Tukey post hoc test, n=3-4. 
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Figure 4.3: Corrected QT interval for male SD rats exposed to PVP capped AgNP 7 days prior 
to assessment. Mean values displayed based on a 10 second sample at: 1, 5, 10, 15 minutes 
into baseline (A) and occlusion (B). 10 second samples were taken at: 1, 5, 10, 15, 25, 30, 45, 
60, 75, 90, 105 and 120 minutes during reperfusion (C).  No differences in PR interval exist.  P 
< 0.05 determined by two-way ANOVA with Tukey post hoc test, n= 2-4.  
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Figure 4.4: Corrected QT interval for male SD rats exposed to citrate capped AgNP 7 days 
prior to assessment. Mean values displayed based on a 10 second sample at: 1, 5, 10, 15 
minutes into baseline (A) and occlusion (B). 10 second samples were taken at: 1, 5, 10, 15, 25, 
30, 45, 60, 75, 90, 105 and 120 minutes during reperfusion (C).  No differences in PR interval 
exist at any time point.  P < 0.05 determined by two-way ANOVA with Tukey post hoc test, n= 
2-4.  
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Figure 4.5: PR interval for male SD rats exposed to PVP capped AgNP 7 days prior to 
assessment. Mean values displayed based on a 10 second sample at: 1, 5, 10, 15 minutes 
into baseline (A) and occlusion (B). 10 second samples were taken at: 1, 5, 10, 15, 25, 30, 45, 
60, 75, 90, 105 and 120 minutes during reperfusion (C).  No differences in PR interval during 
baseline or ischemia exist. Mean PR was lengthened during reperfusion by 20nm AgNP 
compared to vehicle but not naïve.  P < 0.05 determined by two-way ANOVA with Tukey post 
hoc test, n= 2-4.  
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Figure 4.6: PR interval for male SD rats exposed to citrate capped AgNP 7 days prior to 
assessment. Mean values displayed based on a 10 second sample at: 1, 5, 10, 15 minutes 
into baseline (A) and occlusion (B). 10 second samples were taken at: 1, 5, 10, 15, 25, 30, 45, 
60, 75, 90, 105 and 120 minutes during reperfusion (C).  20 nm AgNP reduces PR interval 
compared to vehicle.  P < 0.05 determined by two-way ANOVA with Tukey post hoc test, n= 2-
4. 
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4.3 DISCUSSION 
Despite previous studies demonstrating the ability for pulmonary exposure to PM to 
induce changes in autonomic balance as measured by HR and HR variability (12, 19, 21) 
seven days following post exposure there appears to be no influence on HR. Neither PVP nor 
citrate capped AgNP were demonstrated to induce a significant change in HR.  Despite the 
body of evidence that exposure to PM induces an autonomic imbalance, evidence of AgNP 
influencing autonomic balance is both sparse and conflicting. Exposure to aerosolized AgNP 
has been shown to have no basal impact on HR 7 days following exposure (98). The same 
study did find that a significant increase in HR could be induced with isoproterenol following 
exposure to high doses of AgNP. A zebrafish embryo model of AgNP exposure demonstrated 
a size dependent impact on HR, whereby smaller AgNP were able to induce a greater 
reduction in resting HR (90). Our data is congruent with a lack of particle response in respect 
to HR  7 days post exposure. This thesis only evaluated HR 7 days post exposure, it is 
possible that any changes in autonomic balance do not persist 7 days post exposure but may 
be evident at earlier time points.  
Much like HR, exposure to both PVP and citrate capped AgNP resulted in no changes 
in corrected QT interval. At present, there have been no published studies evaluating the 
impact of exposure to AgNP on QT interval. Much like with HR, data regarding the impact of 
PM exposure on QT interval are conflicting.  Pulmonary exposure to ambient traffic-related 
particulate matter, namely black carbon, has been demonstrated to be associated with an 
increase in QT interval. (8) Interestingly, the same study was unable to show a statistically 
significant change in QT interval following exposure to ultrafine was not associated with the 
same prolongation of QT interval.  The impact of PM exposure on ventricular repolarization 
and QT interval may be delayed in onset, as demonstrated by a human study which showed 
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the greatest changes to QT interval occurred 3 to 4 hours following exposure to ambient fine 
PM (59).  A lack of particle impact on QT interval is also supported by a study of spontaneous 
heart failure prone rats whereby exposure to whole diesel exhaust was unable to induce 
changes in QT interval (20). Pulmonary exposure to PM collected from an urban area on the 
east coast was determined to result in prolonged QT intervals compared to control (134). 
Despite evidence suggesting that exposure to PM may impact ventricular depolarization or 
repolarization events as measured by QT interval, our results demonstrate that exposure to 
AgNP does not result in alterations to QT interval 7 days post exposure.  
Finally, PR interval appears to be differentially impacted by exposure to AgNP. Previous 
studies have found an association between exposure to PM and increased PR interval (20, 
60). Our study demonstrates that exposure to 20 nm AgNP results in capping dependent 
changes in PR interval. Exposure to PVP capped AgNP results in a prolongation of the PR 
interval when compared to vehicle. This response is similar to literature reports regarding 
prolongation of PR intervals following exposure pulmonary exposure to PM. Citrate capped 
AgNP also alter PR interval compared to vehicle control, however unlike PVP citrate results in 
a shortened PR interval, a somewhat surprising response contradictory to previous studies of 
PM as well as to the responses seen in PVP capped AgNP. It may be that surface modification 
of capping agents play an important role on mediating biological responses to AgNP. It may be 
important to note that although some statistical differences were seen in PR intervals these 
only were present in 20nm AgNP and only compared to their direct control. It is suggestive of 
the fact that even at 7 days following instillation of AgNP the 20nm particle is able to elicit a 
small response. It may also be important to note that differences were only detected during 
reperfusion suggesting that particle responses may require a stressor to manifest themselves. 
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It is unclear whether or not changes observed were a result of stress of reperfusion injury or a 
delayed response to ischemic insult.  
  
CHAPTER 5 
INFLAMMATORY RESPONSE to IT INSTILLATION of AgNP 
5.1 INTRODUCTION 
The ability for various PM to induce an inflammatory response has been well 
documented. Exposure to diesel particles has been shown to increase secretion of TNF- , as 
well as IL-6 and IL-1β from human alveolar macrophages (46). Pulmonary responses to PM 
have been shown to stimulate release of polymorphonuclear leukocytes in bone marrow (117) 
which may contribute to a systemic inflammatory response (128).  Furthermore, differential 
cellular response to AgNP may induce a release of cytokines and chemokines from endothelial 
cells which could contribute CV toxicity associated with exposure to AgNP (122).  In order to 
evaluate the inflammatory response to exposure to AgNP we exposed male SD rats to two 
sizes of AgNP with two different capping agents. We measured concentration of several 
circulating cytokines before and after instillation of PM, as well as immediately following I/R 
Injury.   
5.2 RESULTS 
5.2.1 IT INSTILLATION of AgNP DOES NOT RESULT IN INCREASED CONCENTRATION 
of CIRCULATING CYTOKINES 
No differences were noted in serum cytokine concentrations for:  G-CSF, GM-CSF, IL-
1β, IL-2, IL-5, IL-6, IL-10, IL-13, IL-17, IL-18, IFNγ, MIP-1α, TNFα or RANTES at 1, 3, 6, 24, 
28, 48, 72, and 168 hours following IT instillation of AgNP or vehicle.  Concentrations of serum 
cytokines at baseline and following IT instillation are listed for: small PVP (Table 5.2), PVP 
capped 20 nm AgNP (Table 5.3), large PVP (Table 5.4), PVP capped 110 nm AgNP (Table 
5.5), citrate (Table 5.6), citrate capped 20 nm AgNP (Table 5.7) and citrate capped 110 nm 
AgNP (Table 5.8).   
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5.2.2 PVP and CITRATE CAPPED AgNP ELICT DIFFERENTIAL INFLAMATORY 
RESPONSE FOLLOWING I/R INJURY 
Following I/R injury 7 days post IT instillation of AgNP the greatest changes in 
inflammatory cytokine levels from baseline are seen in the 20 nm PVP capped AgNP. Several 
proinflammatory cytokines including IL-2, and IL-18 are significantly increased from baseline 
compared to vehicle (Fig 5.1). Following I/R injury, 7 days post IT instillation, circulating serum 
concentrations of IL-2 and IL-18 were significantly elevated from baseline 138.1 ± 34.4 % and 
153.1 ± 54.0 respectively in the 20 nm PVP capped AgNP. Whereas the corresponding vehicle 
demonstrated a 16.6 ± 17.9 % decrease from baseline in serum IL-2 and only a 5.1 ± 20.0 % 
increase from baseline serum IL-18. Likewise, at 7 days serum IL-6 is elevated 211.0 ± 56.4 % 
from baseline in the 20 nm AgNP versus a depression of 14.7 ± 34.6 from baseline in the small 
PVP vehicle (Fig 5.2). These difference are only demonstrated in the PVP capped AgNP and 
only in the 20 nm variety. No differences were detected between 110 nm PVP capped AgNP 
and the respective vehicle.   Regarding the citrate capped AgNP no differences in 
inflammatory response to I/R exist at 7 days post exposure between 20 nm and 110 nm AgNP 
and citrate vehicle.  
5.2.3 TIME POST IT EXPOSURE IMPACTS INFLAMMATORY RESPONSE TO I/R INJURY 
Serum cytokine profile response to I/R injury following IT instillation of AgNP is 
attenuated at 7 days as compared to the profile and levels seen from 24 hours post AGNP 
exposure. At 24 hours following IT instillation of AgNP induction of I/R injury results in a 89.1 ± 
33.9 % increase in serum IL-6 concentration from baseline compared to a -69.4 ± 14.5.0 % 
decrease from baseline following IT instillation of small PVP vehicle .  At 24 hours cytokine 
release in response to I/R injury following IT instillation of PVP capped 110 nm appears to be 
blunted from baseline compared to large PVP vehicle, -87.9 ± 12.1 % versus an increase of 
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26.4 ± 87.2 %, respectively (Fig 5.2), however no statistical significance exists.  No statistical 
differences were found between citrate, citrate capped 20 nm AgNP and citrate capped 110 
nm AgNP cytokine levels, 24 post exposure, in response to I/R injury.  When the cytokine 
response to I/R injury was evaluated 7 days following IT instillation the relationship between 20 
nm AgNP and small PVP remains consistent; 20 nm AgNP was significantly elevated from 
baseline 211 ± 34.5 % compared to small PVP -14.7 ±  56.4 %.  Citrate capped AgNP groups 
had no statistical differences 7 days following pulmonary exposure from the vehicle control 
levels. Despite similarities in pattern of inflammatory response to I/R injury 24 hours and 7 
days following IT instillation of AgNP, independent of capping agent, the magnitude of 
response had diminished.  
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Table 5.1:  Mean serum cytokine concentrations at baseline. Baseline serum cytokine 
concentration determined by calculating the mean value of cytokine concentrations at time 0 
across individuals for all treatment groups with respective capping agent or vehicle. N/A 
indicated cytokine was not measured for a particular capping agent. Values of cytokine 
concentrations are displayed as mean ± SEM, n=12-16. 
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Cytokine 
PVP Baseline 
Mean ± SEM (pg/mL) 
Citrate Baseline 
Mean ± SEM (pg/mL) 
G-CSF 246.8 ± 24.3 
36.67 ± 8.6 
 
GM-CSF N/A 
1.023 ± 1.0 
 
IL-1β 64.9± 8.0 
7.6 ± 4.8 
 
IL-2 459.6 ± 45.8 
161.7 ± 24.5 
 
IL-5 N/A 
300.2 ± 33.8 
 
 
IL-6 1559.0 ± 226.3 
366.4 ± 125.5 
 
IL-10 N/A 
44.9 ± 10.6 
 
IL-13 N/A 
15.6 ± 4.3 
 
IL-17 N/A 
79.7 ± 10.1 
 
IL-18 391.5 ± 38.3 
151.8 ± 23.3 
 
IFNγ N/A 
38.1 ± 21.3 
 
MIP-1α N/A 
15.7 ± 3.6 
 
MCP-1 2296.0 ± 78.1 N/A 
TNFα 49.9 ± 6.3 
16.6 ±  2.2 
 
RANTES N/A 
963.3  ± 124.1 
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Table 5.2: Serum cytokine concentrations at baseline (0 h) and 1, 3, 6, 24, 48, 72, and 168 
hours following IT instillation of small PVP vehicle. N/A indicates a cytokine was not examined 
at a time point. ND indicates a cytokine fell below detection range. Values are represented as 
a mean of concentration (pg/mL) at each time point ± SEM, n= 4.  
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Small 
PVP 
0h +1h +3h +6h +24h +48h +72h +168h 
G-CSF 
253.4 
± 23.8 
163.7 ± 
48.4 
123.4 ± 
40.7 
178.9 ± 
37.6 
246.7 ± 
22.1 
140.0 ± 
33.1 
118.6 ± 
46.5 
119.9 ± 
39.3 
IL-1β 
58.9 ± 
13.9 
63.7 ± 
13.00 
58.9 ± 
13.9 
58.0 ± 
4.3 
57.1 ± 
7.3 
51.0 ± 
8.2 
41.1 ± 
9.4 
40.67 ± 
11.4 
IL-2 
358.7 ± 
37.1 
219.3 ± 
80.3 
151.5 ± 
29.2 
251.4 ± 
50.2 
294.6 ± 
13.3 
229.1 ± 
17.5 
188.6 ± 
58.8 
194.9 ± 
61.6 
IL-6 
846.6 ± 
151.6 
824.7 ± 
211.2 
558.3 ± 
198.8 
455.7 ± 
160.1 
497.8 ± 
100.4 
197.4 ± 
123.6 
277.0 ± 
102.1 
222.3 ± 
162.7 
IL-18 
293.9 ± 
30.9 
183.5 ± 
55.2 
128.5 ± 
25.5 
226.6 ± 
24.5 
210.0 ± 
15.8 
195.3 ± 
26.0 
149.2 ± 
47.2 
160.4 ± 
54.4 
MCP-1 
2109 ± 
103.5 
1820 ± 
279.0 
1580 ± 
277.4 
1909 ± 
185.2 
1935 ± 
77.0 
1668 ± 
118.1 
1418 ± 
327.5 
1358 ± 
207.6 
TNFα 
82.6 ± 
7.9 
61.8 ± 
16.1 
47.5 ± 
13.2 
63.2 ± 
12.1 
67.5 ± 
3.7 
49.3 ± 
2.9 
37.1 ± 
13.7 
41.8± 
11.6 
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Table 5.3: Serum cytokine concentrations at baseline (0h) and 1, 3, 6, 24, 48, 72, and 168 
hours following IT instillation of PVP capped 20 nm AgNP. N/A indicates a cytokine was not 
examines at a time point. ND indicates a cytokine fell below detection range. Values are 
represented as a mean of concentration (pg/mL) at each time point ± SEM, n= 4. 
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20 nm 
AgNP/PVP 
0h +1h +3h +6h +24h +48h +72h +168h 
G-CSF 
342.6 ± 
50.8 
328.8 ± 
45.8 
329.8 ± 
40.1 
316.6 ± 
83.8 
281.8 ± 
27.9 
256.9 ± 
26.4 
208.0 ± 
34.3 
312.9 ± 
107.9 
IL-1β 
40.7 ± 
11.42 
64.4 ± 
23.66 
53.2 ± 
11.17 
48.3 ± 
16.41 
48.0 ± 
18.1 
21.37 ± 
15.2 
39.58 ± 
27.5 
42.47 ± 
15.6 
IL-2 
658.7 ± 
110.4 
691.9 ± 
111.4 
618.2 ± 
39.58 
563.2 ± 
120.7 
637.7 ± 
29.62 
465.2 ± 
160.9 
513.2 ± 
91.29 
703.4 ± 
213.0 
IL-6 
2380  ± 
567.9 
2382 ± 
699.3 
2111 ± 
255.7 
1984 ± 
667.1 
1260 ± 
316.1 
992.6 ± 
380.0 
1114 ± 
505.5 
2228 ± 
1086 
IL-18 
547.0 ± 
88.6 
540.9 ± 
78.7 
479.1 ± 
28.5 
469.6 ± 
87.2 
466.2 ± 
21.5 
332.1 ±  
133.8 
426.6 ± 
102.7 
589.2 ± 
192.6 
MCP-1 
2592  ± 
122.6 
2676 ± 
196.2 
2629 ± 
88.59 
2484 ± 
257.5 
2494 ± 
139.0 
1954 ± 
371.9 
2146 ± 
215.6 
2606 ± 
419.8 
TNFα 
42.6 ± 
6.0 
47.3 ± 
5.9 
46.8 ± 
4.0 
41.3 ± 
8.2 
42.6 ± 
4.4 
28.5 ± 
9.4 
32.9 ± 
5.9 
48.7 ± 
15.9 
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Table 5.4: Serum cytokine concentrations at baseline (0h) and 1, 3, 6, 24, 48, 72, and 168 
hours following IT instillation of large PVP vehicle. N/A indicates a cytokine was not examines 
at a time point. ND indicates a cytokine fell below detection range. Values are represented as 
a mean of concentration (pg/mL) at each time point ± SEM, n=4.  
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Large PVP 0h +1h +3h +6h +24h +48h +72h +168h 
G-CSF 
178.8 ± 
23.4 
220.1 
± 62.3 
110.2 ± 
44.2 
91.8 ± 
54.3 
206.6 ± 
81.0 
266.5 ± 
52.9 
158.2 ± 
24.8 
237.6 ± 
30.4 
IL-1β 
72.3 ± 
13.0 
83.8 ± 
29.7 
32.5 ± 
19.3 
33.2 ± 
19.9 
100.4 ± 
24.1 
99.7 ± 
17.3 
47.2 ± 
18.7 
105.2 ± 
14.8 
IL-2 
395.7 ± 
89.5 
403.1 
± 
106.2 
203.2 ± 
64.0 
182.9 ± 
91.2 
348.9 ± 
117.3 
503.3 ± 
93.9 
306.1 ± 
54.8 
433.5 ± 
76.0 
IL-6 
1174  ± 
354.4 
1101 ± 
509.5 
243.2 ± 
172.6 
284.9 ± 
271.9 
900.4 ± 
550.2 
1302 ± 
290.3 
705.4 ± 
368.8 
1549 ± 
236.8 
IL-18 
343.2 ± 
83.3 
315.1 
± 
105.1 
189.3 ± 
71.5 
153.0 ± 
68.0 
254.8 ± 
110.8 
402.0 ± 
74.8 
263.3 ± 
38.5 
385.1 ± 
60.3 
MCP-1 
2333  ±    
194.6 
2278 ± 
336.3 
1687 ± 
234.1 
1617 ± 
279.3 
1840 ± 
681.1 
2496 ± 
227.7 
2022 ± 
139.1 
2633 ± 
353.2 
TNFα 
42.95 ± 
13.3 
48.64 
± 14.4 
22.67 ± 
9.9 
13.22 ± 
10.4 
73.45 ± 
28.8 
60.20 ± 
12.2 
32.10 ± 
6.2 
50.52 ±  
10.7 
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Table 5.5: Serum cytokine concentrations at baseline (0h) and 1, 3, 6, 24, 48, 72, and 168 
hours following IT instillation of PVP capped 110 nm AgNP.  N/A indicates a cytokine was not 
examines at a time point. ND indicates a cytokine fell below detection range.  Values are 
represented as a mean of concentration (pg/mL) at each time point ± SEM, n= 4 
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110 nm 
AgNP/PVP 
0h +1h +3h +6h +24h +48h +72h +168h 
G-CSF 
212.3 ± 
55.8 
174.1 ± 
14.6 
93.3  ± 
21.8 
143.0 ± 
19.6 
129.4 ± 
27.5 
177.5 ± 
33.5 
181.2 
± 21.4 
123.9 ± 
24.3 
IL-1β 
87.8 ± 
19.9 
97.9± 
13.2 
40.5 ± 
14.1 
82.5 ± 
16.2 
68.6 ± 
6.5 
101.9 ± 
10.3 
95.4 ± 
17.0 
57.3 ± 
11.0 
IL-2 
425.3 ± 
45.2 
419.6 ± 
25.5 
256.7 ± 
32.0 
379.3 ± 
41.8 
356.2 ± 
35.7 
453.7 ± 
60.8 
465.2 
± 55.7 
321.8 ± 
33.9 
IL-6 
1715  ±  
321.4 
1749 ± 
126.5 
584.1 ± 
313.0 
1501 ± 
289.6 
875.3 ± 
321.0 
1713 ± 
545.7 
1914 ± 
285.9 
1167 ± 
518.4 
IL-18 
382.0 ± 
39.0 
411.0 ± 
50.0 
226.5 ± 
46.2 
331.8 ± 
51.17 
286.0 ± 
39.9 
412.1 ± 
45.9 
417.1 
± 51.2 
315.6 ± 
49.7 
MCP-1 
2149  ± 
98.8 
2204 ± 
93.3 
1615 ± 
194.8 
1958 ± 
49.4 
1860 ± 
114.1 
2122 ± 
190.4 
2103 ± 
127.6 
1816 ± 
171.0 
TNFα 
31.7 ± 
3.2 
30.8 ± 
2.0 
17.2 ± 
4.6 
23.8 ± 
2.1 
22.9 ± 
3.5 
34.3 ± 
7.1 
33.7 ± 
5.4 
22.2 ± 
3.8 
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Table 5.6: Serum cytokine concentrations at baseline (0h) and 1, 3, 6, 24, 48, 72, and 168 
hours following IT instillation of citrate vehicle. N/A indicates a cytokine was not examines at a 
time point. ND indicates a cytokine fell below detection range.  Values are represented as a 
mean of concentration (pg/mL) at each time point ± SEM, n=  4 
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  Citrate 0h +3h +24h +168h 
G-CSF 
31.9 ± 
10.4 
45.6 ± 
16.1 
59.0± 
21.5 
23.2 ± 
10.5 
GM-CSF ND ND ND 
10.9± 
10.9 
IL-1β 
5.1 ± 
5.1 
7.605 ± 
3.8 
1.685 ± 
1.4 
11.6 ± 
11.6 
IL-2 
138.1 ± 
14.01 
150.5 ± 
31.7 
109.6 ± 
29.3 
175.1 ± 
65.3 
IL-5 
299.1 ± 
27.7 
305.6 ± 
43.5 
243.1 ± 
43.6 
351.2 ± 
79.6 
IL-6 
299.3 ± 
136.7 
587.8 ± 
234.4 
43.3 ± 
43.3 
590.1 ± 
484.2 
IL-10 
38.1 ± 
8.2 
42.6 ± 
11.6 
23.9± 8.1 
51.3 ± 
31.2 
IL-13 
14.4  ±  
7.5 
19.5 ± 
8.2 
ND 
20.66 ± 
20.7 
IL-17 
74.5 ± 
5.5 
83.9± 
17.9 
54.62 ± 
18.2 
94.7 ± 
37.9 
IL-18 
138.9 ± 
20.6 
133.2 ± 
38.0 
91.7 ± 
28.1 
169.7 ± 
75.9 
IFNγ 
54.8 ± 
54.8 
117.4 ± 
42.3 
ND 
186.6 ± 
186.6 
MIP-1α 
25.2 ± 
2.0 
26.1 ± 
3.4 
20.9 ± 
3.7 
28.2 ± 
8.9 
MCP-1 N/A N/A N/A N/A 
TNFα 
14.9 ± 
1.4 
16.0± 2.7 
12.6 ± 
2.9 
18.4 ± 
6.2 
RANTES 
799.4 ± 
192.7 
683.1 ± 
126.8 
720.7 ± 
26.8 
662.9 ± 
130.3 
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Table 5.7: Serum cytokine concentrations at baseline (0h) and 1, 3, 6, 24, 48, 72, and 168 
hours following IT instillation of citrate capped 20 nm AgNP.  N/A indicates a cytokine was not 
examines at a time point. ND indicates a cytokine fell below detection range. Values are 
represented as a mean of concentration (pg/mL) at each time point ± SEM, n =4.  
 
 
63 
 
  
20 nm 
AgNP/C
itrate 
0h +3h +24h +168h 
G-CSF 
32.8 ± 
11.2 
55.9 ± 
23.6 
51.7 ± 
16.5 
42.8 ± 
25.3 
GM-CSF ND ND 
3.835 ± 
3.835 
ND 
IL-1β 3.5 ± 1.5 12.6 ± 9.2 8.0 ± 4.3 4.1± 2.4 
IL-2 
107.5 ± 
32.1 
169.7 ± 
52.3 
181.2 ± 
32.7 
114.0 ± 
26.5 
IL-5 
229.3 ± 
77.5 
331.8 ± 
62.4 
374.3 ± 
32.0 
284.2 ± 
36.6 
IL-6 
114.3 ± 
68.1 
351.8 ± 
214.6 
444.5 ± 
346.9 
93.0 ± 
53.7 
IL-10 26.3 ± 8.8 
39.9 ± 
16.7 
54.5 ± 
16.2 
27.0 ± 
10.5 
IL-13 
10.45 ± 
4.0 
19.09 ± 
7.5 
23.65 ± 
16.5 
0.8± 0.8 
IL-17 
62.44 ± 
20.9 
86.35 ± 
27.5 
98.89 ± 
17.8 
63.2 ± 
17.2 
IL-18 
107.0 ± 
36.1 
151.3 ± 
55.8 
184.7 ± 
43.0 
108.7 ± 
27.7 
IFNγ 
34.2 ± 
34.2 
75.2 ± 
59.6 
140.7 ± 
140.7 
7.7 ± 7.7 
MIP-1α 18.7 ± 6.3 26.5 ± 6.3 29.3 ± 3.4 19.6 ± 4.1 
MCP-1 N/A N/A N/A N/A 
TNFα 
11.72 ± 
3.0 
18.8 ± 5.2 
18.77 ± 
3.6 
13.01 ± 
2.7 
RANTES 
828.1 ± 
153.2 
807.8 ± 
27.4 
746.1 ± 
92.1 
652.8 ± 
88.5 
 
 
64 
 
Table 5.8: Serum cytokine concentrations at baseline (0h) and 1, 3, 6, 24, 48, 72, and 168 
hours following IT instillation of citrate capped 110 nm AgNP. N/A indicates a cytokine was not 
examines at a time point. ND indicates a cytokine fell below detection range. Values are 
represented as a mean of concentration (pg/mL) at each time point ± SEM, n= 4  
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110 nm 
AgNP/Citrate 
0h +3h +24h +168h 
G-CSF 
212.3 ± 
55.8 
43.5 ± 
7.5 
11.1 ± 
3.9 
53.0 ±  
38.2 
GM-CSF 3.1 ± 3.1 1.2 ± 1.2 ND ND 
IL-1β 
14.3 ± 
14.3 
7.6± 3.8 
12.1 ± 
8.7 
11.6 ±  
11.6 
IL-2 
239.4 ± 
46.7 
225.0 ± 
57.5 
259.2 ± 
42.9 
126.7 ± 
60.7 
IL-5 
372.3 ± 
48.7 
361.0 ± 
56.7 
385.7 ± 
33.1 
249.6 ± 
75.4 
IL-6 
685.5 ± 
305.6 
636.8 ± 
355.2 
508.6 ± 
286.5 
495.4 ± 
286.0 
IL-10 
70.2 ± 
27.1 
75.9 ± 
26.8 
74.1 ± 
16.0 
43.5 ± 
 26.7 
IL-13 
22.0 ± 
10.4 
22.6 ± 
13.1 
17.2 ± 
10.2 
21.5 ±  
13.6 
IL-17 
102.2 ± 
19.3 
94.0 ± 
22.0 
108.3 ± 
17.4 
53.4 ±  
31.7 
IL-18 
209.5 ± 
49.1 
218.0 ± 
63.1 
212.8 ± 
40.9 
119.9 ± 
69.8 
IFNγ 
25.4 ± 
25.4 
45.0 ± 
28.9 
ND 
102.0 ± 
102.0 
MIP-1α 
39.01 ± 
7.6 
37.4 ± 
8.2 
40.2 ± 
4.5 
23.1 ±  
8.9 
MCP-1 N/A N/A N/A N/A 
TNFα 
23.2 ± 
4.4 
21.1 ± 
5.6 
23.7 ± 
4.5 
12.4 ±  
5.5 
RANTES 
1262  ± 
253.1 
1179 ± 
215.9 
1192 ± 
116.1 
829.3 ± 
229.8 
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Figure 5.1: Serum cytokine concentrations changes from baseline to 7 day post exposure I/R 
injury. 20 nm PVP capped AgNP elicited a greater inflammatory response following I/R injury 
when compared to vehicle than Citrate capped AgNP. a denotes statistical significance from 
vehicle p< 0.05 by t-test, n= 4. No differences exist within the Citrate capped groups or vehicle.   
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Figure 5.2: Changes in serum IL-6 concentrations from baseline following I/R injury at 1 and 7 
days after IT instillation. When I/R injury is induced 24 hours or 7 days following IT instillation, 
exposure to 20 nm PVP capped AgNP results in the greatest release of inflammatory cytokines 
compared to vehicle (A) which persists at 7 days (B). No differences were detected in citrate 
capped AgNP at 24 hours (C) or 7 days (D). Overall, strength of inflammatory response varies 
depending on particle size from 1 to 7 days in PVP capped AgNP while citrate capping results 
in a greater inflammatory response to I/R injury from 1 to 7 days after exposure. a denotes 
statistical significance from vehicle p< 0.05 by t-test, n= 4.
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5.3 DISCUSSION 
 There has been much investigation into the role of pulmonary exposure to various forms 
of PM and the ability to induce an inflammatory response (79, 110, 129). However, the 
mechanisms through which AgNPs generate inflammatory responses are less than clear. We 
hypothesized that IT instillation of AgNP would result in a systemic inflammatory response 
measured by circulating cytokines and chemokines. IT exposure to AgNP does not generate a 
strong inflammatory response compared to naïve or vehicle groups.  However, there is 
literature to suggest that exposure to PM alone, particularly engineered nano particles, is 
insufficient to induce a strong inflammatory response (54).  It may be that exposure to 
engineered nanomaterials such as AgNP result in changes to inflammatory set points whereby 
an initial exposure to AgNP results in minor a release of inflammatory mediators such as 
cytokines and chemokines but a secondary insult results in an exaggerated inflammatory 
response compared to vehicle control (95).  Our model utilized cardiac ischemia reperfusion as 
our secondary injury whereby we examined the impact of particle exposure on the 
inflammatory response to ischemia reperfusion injury. Induction of ischemia reperfusion injury 
resulted in increases of several circulating cytokines including IL-2, IL-6, and IL-18 that was 
exaggerated when compared to the response with naive or vehicle alone treatment groups.  
 The observed particle response appears to be largely dependent on size and capping 
agent.  Exposure to 20 nm AgNP consistently induces a greater increase in selected pro 
inflammatory cytokines compared to vehicle control than did the 110 nm AgNP exposure.  
These increases were only ascribed to the PVP capped AgNP group. Interestingly, PVP 
capping of 110 nm AgNP appeared to reduce circulating levels of IL-6 compared to control 
vehicle and 20 nm AgNP at 24 hours post exposure. This differential response may be further 
evidence of a size-capping agent dependent inflammatory response.  Our data revealed that 
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24 hours following IT instillation of AgNP elicited a greater inflammatory response in 20 nm 
PVP capped AgNP than 20 nm citrate following I/R injury as reflected by greater levels of 
selected pro-inflammatory cytokines found in the serum. Intratracheal exposure to citrate 
capped AgNP demonstrated no difference in response compared to its vehicle control. The 
differential response to various size particle and capping agents may be related to the 
formation of protein coronas (108) which reflect differing biological interactions with the 
capping agents. The formation of unique protein coronas based on the capping material may 
influence the inflammatory response to AgNP by modulating the way nanomaterials interact 
with cells or tissues. Independent of the formation of protein coronas, the capping agents may 
also influence nanoparticle interactions at biological interfaces (27). One study of gold 
nanoparticles revealed different capping agents have the ability to elicit differential effects on 
both in vitro and in vivo toxicity (30). The results of this study allow us to suggest that different 
capping agents may have the ability to change the manner in which capped AgNP may impact 
toxicity.  
 The final aspect of the inflammatory response to AgNP is the duration of response. The 
increase in circulating cytokines (i.e. IL-6) to PVP capped 20 nm AgNP is diminished following 
I/R injury at 7 days post exposure compared to 24 hours. In contrast, 7 days post exposure 
110 nm PVP capped AgNP had a greater levels of circulating IL-6 in response to I/R injury 
than at 24 hours. Citrate capped AgNP resulted in no differences between control vehicle and 
20 or 110 nm AgNP following I/R injury at 24 hours post IT instillation. Citrate capped AgNP 
also resulted in diminished levels of IL-6 at 7 days following I/R injury compared to 24 hours.    
These observations may indicate a time-dependent aspect of particle size-capping 
interactions.            
CHAPTER 6 
INTEGRATED DISCUSSION AND CONCLUSION 
6.1 DISCUSSION 
 The rapidly expanding uses of engineered nanomaterials have raised questions 
regarding the safety of exposure to such particles. To date, there is little consensus regarding 
the safety of engineered nanomaterials or the mechanisms by which they may induce a toxic 
response. This thesis evaluated the impact of pulmonary exposures to silver nanoparticles  
(AgNP) on myocardial ischemia reperfusion (I/R) injury. We hypothesized that intratracheal (IT) 
instillation of AgNP would result expansion of I/R injury. This hypothesis was based on the 
interpretation of effects of previously investigated particulate matter and nanomaterials 
including but not limited to: diesel (71), C60 fullerene (14), and multi-wall carbon nanotubes 
(MWCNT) (91). Currently, it is thought that pulmonary exposure to PM and engineered 
nanomaterials can lead to cardiovascular disease and dysfunction through multiple pathways 
(63, 13). One proposed pathway involves PM directly stimulating sensory fibers within the lung 
stimulating pulmonary-neural reflex arcs that can alter the sympathetic or parasympathetic 
balance in the heart leading to changes in heart rate, heart rate variability, cardiac conduction 
and repolarization, arrythmogenesis, and blood pressure (13, 63, 66). Activation of pulmonary-
neural reflex arcs can also lead to increased release of cytokines which may be augmented by 
PM induced decreases in vagal tone inhibiting neuronal regulation of inflammation (75). A 
second proposed pathway involves particulate induced oxidative stress in the lungs leading to 
inflammatory responses including the release of cytokines (58, 111), which leads to systemic 
inflammation and cardiovascular dysfunction (63). We examined several endpoints of AgNP 
toxicity: 1) autonomic and cardiac electrical dysfunction as measured by HR, PR interval, and 
QT interval, 2) systemic inflammation as measured by serum cytokine levels, 3) exacerbation 
of myocardial I/R injury following AgNP exposure. A final element of toxicity unique to AgNP is 
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the direct impact of ionic silver on cardiovascular toxicity, which was evaluated by examining 
the expansion of cardiac I/R injury following instillation of several concentrations of silver ions. 
The proposed mechanisms by which pulmonary exposure to AgNP elicits cardiovascular 
toxicity and exacerbates cardiac I/R injury as well as how our aims relate are summarized in 
figure 6.1.   We determined that exposure to AgNP results in expansion of myocardial 
infarction following a course of coronary artery occlusion and subsequent reperfusion occurring 
24 hours following IT instillation as well as 7 days following instillation.  Despite demonstrating 
that AgNP have the ability to expand I/R injury the mechanisms through which AgNP may 
influence the expansion of I/R injury remains unclear. 
 The balance of autonomic control in the heart is crucial for normal cardiac function. 
Changes in parasympathetic and sympathetic tone may underlie cardiac disease. 
Furthermore, dysregulation of autonomic balance has been associated with increased mortality 
from cardiovascular disease (CVD) (88). In order to evaluate the effect of AgNP on electrical 
activity in the heart as a measure of autonomic balance we measured heart rate (HR), PR 
interval, and QT interval. Heart rate has long been used as a measure of autonomic balance 
as well as being an independent risk for cardiovascular mortality (88). Sympathetic and 
parasympathetic innervation of the sinoatrial node control HR through a balance of excitatory 
and inhibitory inputs;  this balance can be modulated by psychosocial stressors (23) as well as 
various toxicants, such as PM (24, 113, 133).  Our study demonstrated that IT instillation of 
AgNP did not result in significant changes in heart rate. Alterations in QT interval may be an 
important indicator of cardiotoxicity (7, 45) whereby QT prolongation can lead to increased 
arrhythmogenesis and sudden cardiac death (2, 56).We also report that exposure to AgNP did 
not significantly impact electrical activity in terms of ventricular depolarization and 
repolarization times as measured by QT interval.  Despite finding no differences in HR and QT 
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interval following exposure to AgNP, our analysis did uncover differences in PR interval during 
reperfusion in AgNP exposed SD rats, compared to vehicle.  The PR interval reflects the time it 
takes for an impulse to be conducted from the atria to the ventricles via the atrioventricular 
node (89).  The duration of the PR interval in large part is dictated by a balance of autonomic 
tone whereby a shift towards parasympathetic or sympathetic dominance can increase or 
decrease PR interval, respectively. Our data suggests that exposure to 20 nm AgNP may 
influence vagal tone following a period of myocardial ischemia, and that the capping agent may 
differentially impact autonomic tone. In light of the differential responses to AgNP capping 
agents, selection of appropriate capping agents may be crucial to avoid unwanted 
cardiovascular toxicity associated with pulmonary exposure to AgNP.   Several caveats must 
be considered when interpreting our electrocardiogram (ECG) data.  First, only ECGs from 
surgeries 7 days post exposure were evaluated for HR, PR, and QT. It may be possible that 7 
days following exposure any changes in autonomic balance or electrical activity induced by 
AgNP may have resolved. Pulmonary exposure to fine PM has been associated with changes 
in ventricular repolarization occurring with 3-4 hours of exposure (60).  Earlier time points 
should be evaluated for changes in autonomic function and electrical activity. Second, all ECG 
recordings were performed under conditions of general anesthesia with ketamine/xylazine 
which may have influenced autonomic tone at the time of surgery and may blunt autonomic 
and electrical responses to AgNP (116). 
 We initially hypothesized that IT instillation of AgNP would result in a systemic 
inflammatory response, which could then drive the expansion of I/R injury. In order to assess 
the inflammatory response we quantified serum levels of several cytokines and chemokines 
which are known to be associated with either particulate matter (PM) exposure or CVD. 
Serially collected serum samples revealed no temporal relationship between IT instillation of 
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AgNP and circulating levels of cytokines. Interestingly, even though there was no increase in 
circulating cytokines prior to I/R injury, exposure to AgNP lead to increased presence of 
several inflammatory cytokines (i.e., IL-2, IL-6, IL-18) following I/R injury compared to pre-IT 
instillation levels .  Although, I/R injury is associated with increases in inflammatory cytokines 
such as IL-6 (14, 139) and IL-18 (30, 61, 92) the extent of cardiac I/R injury does not correlate 
to changes in circulating cytokines. Although not directly related to cardiac I/R injury, IL-2 may 
mediate organ specific proinflammatory mechanisms through control of T-cell differentiation 
and control of Th2 cytokine response (48, 50). The lack of correlation between circulating 
cytokines and the extent of I/R injury suggest that the observed cytokine response is not being 
driven by I/R injury. Furthermore, the increases in serum IL-2, IL-6, and IL-18 are only 
observed in rats exposed to 20nm AgNP, which may indicate an interaction between particle 
size and capping agent drives post I/R injury inflammation.  This finding further allows us to 
suggest an alternate hypothesis; engineered nanomaterials may not directly induce an 
inflammatory response but exacerbate the inflammatory response to a secondary insult, such 
as inoculation with lipopolysaccharide (LPS) (49). Previous studies investigating the role of 
exposure to engineered nanomaterials and the development of pulmonary fibrosis in rats 
demonstrated that exposure to nanomaterials alone were insufficient to induce fibrosis, 
however inoculation with LPS following MWCNT exposure was able to induce fibrotic changes 
greater than LPS or MWCNT alone (25).   This may evidence the ability for AgNP to 
exacerbate inflammatory responses within I/R injury and ultimately expand myocardial I/R 
injury. Although we were unable to demonstrate a strong inflammatory response to instillation 
of AgNP in serum samples, analysis of cytokines localized to tissues of interest, such as 
myocardium, may be a more appropriate target of investigation.  Overall,  the limited changes 
in circulating cytokine concentrations post exposure to AgNP appear to result from 
 
 
76 
 
sensitization of the immune system in response to a secondary insult are largely correlated  
with capping agents and particle size. IT instillation of 20 nm PVP capped AgNP induced a 
greater rise in concentrations of select cytokines (i.e., IL-2, IL-6, IL-18) compared to vehicle 
than citrate capped AgNP. IT instillation of both PVP and citrate capped AgNP 110 nm 
particles resulted in no significant differences from vehicle controls. These results allow us to 
suggest that particle size is an important factor when evaluating the toxicity associated with 
exposure to AgNP. 
 The contribution of ionic silver (Ag+) dissociation to cardiovascular toxicity cannot be 
overlooked, especially regarding AgNP. Silver has long been known to have innate 
toxicological properties. However, biological responses to ionic silver vary widely by cell or 
tissue type as well as species according to a review by Chernousova et al. (26). The direct 
cardiovascular toxicity associated with exposure to ionic silver has been the subject of little 
investigation, however oral ingestion of silver nitrate or silver chloride was associated with left 
ventricular hypertrophy following long term exposure to silver (83). However, this thesis did 
reveal a concentration dependent expansion of I/R injury following exposure to 0.1 mg/mL and 
1 mg/mL concentrations of silver acetate (AgAc).  The direct mechanisms of silver ion 
cardiotoxicity are unclear; however oxidative stress has been demonstrated to increase 
following exposure to ionic silver in cell culture (28). Silver ions can induce oxidative stress via 
multiple mechanisms including direct catalyzation of superoxide radicles from O2 (28), or by 
interacting with thiol groups of respiratory chain enzymes (69, 4).  A rise in oxidative stress 
resulting from exposure to AgNP may explain how a secondary insult (e.g., I/R, LPS) manifests 
as an exaggerated inflammatory response without an initial rise in inflammatory markers (i.e., 
cytokines) following instillation (5). Given Ag+ ionic dissociation from nanomaterials of between 
1 and 30 percent (9, 74, 112) and the relationship of concentrations of AgAc to I/R injury (fig 
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3.5) we believe that free silver ions play a contributing role in the toxicological end points 
examined. However, ionic dissolution is unlikely to be the sole source of toxicity following 
exposure to AgNP because only the highest concentration of AgAc resulted in an I/R injury 
roughly equivalent to 20 nm AgNP; 110 nm AgNPs were able to induce expansion of I/R injury 
equivalent with 20 nm AgNP at 24 hours despite slower ionic dissolution rates due to smaller 
surface area.   
 A fundamental question regarding the toxicity of AgNP is whether or not differences in 
particle number or mass dosing influences our toxicological end points.  Traditionally 
toxicology underscores to the classical adage, “the dose makes the toxin” but that can 
expressed either in either mass or surface area/ article number. Given the different sizes of 
AgNP but an equivalent mass delivered in these studies it is reasonable to assume that there 
are higher numbers of particles in a fixed 200 µL sample of 20 nm AgNP than 110 nm AgNP. 
However, we demonstrated that there is no significant difference in I/R injury 24 hours 
following IT instillation of AgNPs. At 24 hours it seems that particle number is not strongly 
associated with the extent of I/R injury. Furthermore, 7 days following IT exposure a differential 
response is seen between the citrate capped (Fig 3.4) and PVP (Fig 3.3) capped AgNP, 
suggestive of influence of capping agent on the cardiac I/R injury response.  It is possible that 
the cardiac I/R endpoint may simply be insensitive to particle number induced toxicity. Results 
from the cytokine concentrations may indicate that surface area of AgNP along with capping 
agent play the more prominent roles in inducing cardiovascular toxicity. Increased surface area 
may lead to increased ionic dissociation as well as availability for interaction at biological 
interfaces (102).  The capping agents of AgNP may further modulate the way particles interact 
with aforementioned biological interfaces leading to increased toxicity (30).  The influence of 
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capping agent on cardiovascular toxicity may result from differences in surface charge, which 
can impact particle adsorption affinity for cellular surfaces (11) as well as cellular uptake (41).   
 Although it does not appear citrate capped or 110 nm AgNP have a strong influence on 
systemic inflammatory response or myocardial electrical activity, there is a strong effect on the 
expansion of I/R injury.  We suggest that AgNP mediated systemic inflammation or electrical 
dysfunctions are not the only mechanisms contributing to expansion of I/R injury.  Potential 
alternative mechanisms of AgNP toxicity include induction of oxidative stress (28, 74), or 
vascular dysfunction (12, 18, 77) which lead to an expansion of I/R injury 24 hours and 7 days 
following IT exposure to AgNP.  Furthermore cardiovascular toxicity of AgNP likely stem from a 
complex interaction of surface area and capping agents which modulate ionic dissolution and 
nanoparticle interactions with biological interfaces in vivo. 
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Figure 6.1: Proposed mechanisms by which pulmonary exposure to AgNP induces 
cardiovascular toxicity. Pulmonary exposure to AgNP results in cardiovascular toxicity by 
activation of sensory fibers that initiate an inflammatory cascade and cytokine release, as well 
as feedback to the autonomic nervous system altering the balance of sympathetic and 
parasympathetic tone altering: heart rate, cardiac conduction, and cardiac repolarization. 
Additionally, AgNP induction of oxidative stress within the lungs may lead to systemic cytokine 
release and exacerbate cardiac ischemia reperfusion injury. 
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6.2 CONCLUSION   
 The ubiquitous use of engineered nanomaterials makes understanding the potential 
toxicological outcomes of exposure to such materials chief public health concern. We 
investigated the cardiovascular toxicity associated with pulmonary exposure to AgNP. In order 
to evaluate the cardiovascular toxicity associated with exposure to AgNP we evaluated 
measures of electrical and autonomic dysfunction, as well as investigated the impact of AgNP 
on cardiac I/R injury.  In an attempt to elucidate mechanisms of AgNP toxicity we also 
evaluated the inflammatory response to AgNP which we hypothesized to drive expansion of 
I/R injury. Our data reveals that IT instillation of AgNP results in expansion of cardiac I/R injury 
24 hours and 7 days compared to naïve and vehicle controls. Furthermore, IT instillation of 
AgNP did not significantly impact HR or QT interval, but did impact PR interval during 
reperfusion. Instillation of AgNP did not elicit a strong inflammatory response as measured by 
circulating cytokines, but I/R injury following IT instillation did result in a greater inflammatory 
response in PVP capped 20nm AgNP compared to vehicle controls. The cardiovascular 
toxicity of AgNP seems to be dependent on several factors including: particle size, capping 
agent, and ionic dissolution. Future investigations should focus on uncovering the mechanisms 
that underlie the cardiovascular toxicity associated with exposure to AgNP. Additionally, 
determining the persistence of cardiac I/R injury beyond the 7 day time point may be important 
in understanding the potential public health impact of pulmonary exposures to AgNP.   
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